Boehringer Ingelheim to start late-stage hepatitis C drug trial

BOSTON (Reuters) - Boehringer Ingelheim said on Saturday it plans to initiate a late-stage clinical trial of its experimental hepatitis C treatment following promising results from earlier studies.

via Reuters: Health News Read More Here..